Ignite Creation Date:
2025-12-24 @ 5:29 PM
Ignite Modification Date:
2026-02-25 @ 5:49 PM
Study NCT ID:
NCT01946568
Status:
COMPLETED
Last Update Posted:
2015-06-23
First Post:
2013-08-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
Sponsor:
Durata Therapeutics Inc., an affiliate of Allergan plc
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
DUR001-106
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None